Lack of Weight Gain and Relapse Risk in a Large Tuberculosis Treatment Trial
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Readily identified markers of tuberculosis relapse risk are needed, particularly in resource-limited settings. The association between weight gain or loss during antituberculosis therapy and relapse has not been well studied. METHODS: Subjects in the Tuberculosis Trials Consortium Study 22 were studied. Underweight was defined as 10% or more below ideal body weight at diagnosis. Weight change was assessed between (1) diagnosis and completion of induction phase therapy, (2) diagnosis and end of continuation phase therapy, and (3) completion of induction to completion of continuation phase therapy. RESULTS: A total of 857 subjects were monitored for 2 yr, and 61 of 857 (7.1%) relapsed. Relapse risk was high among persons who were underweight at diagnosis (19.1 vs. 4.8%; p < 0.001) or who had a body mass index of less than 18.5 kg/m(2) (19.5 vs. 5.8%; p < 0.001). Among persons who were underweight at diagnosis, weight gain of 5% or less between diagnosis and completion of 2-mo intensive phase therapy was moderately associated with an increased relapse risk (18.4 vs. 10.3%; relative risk, 1.79, 95% confidence interval, 0.96-3.32; p = 0.06). In a multivariate logistic regression model that was adjusted for other risk factors, a weight gain of 5% or less between diagnosis and completion of 2-mo intensive phase therapy among persons underweight at diagnosis was significantly associated with relapse risk (odds ratio, 2.4; p = 0.03). CONCLUSIONS: Among persons underweight at diagnosis, weight gain of 5% or less during the first 2 mo of treatment is associated with an increased relapse risk. Such high-risk patients can be easily identified, even in resource-poor settings. Additional studies are warranted to identify interventions to decrease risk of relapse in such patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1998) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/68.4.899 · Cited by 2,700
van Embden, J. D., Cave, M. D., Crawford, J. T., Dale, J. W., Eisenach, K. D., Gicquel, B., Hermans, P., Martin, C., McAdam, R., & Shinnick, T. M. (1993) · Journal of Clinical Microbiology · doi:10.1128/jcm.31.2.406-409.1993 · Cited by 2,342 · cited 1×
“Initial isolates of Mycobacterium tuberculosis and isolates from any cultures positive after therapy underwent genotyping by IS6110-based restriction fragment length polymorphism analysis using the standardized method (11), as described previously (12).”
(2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.167.4.603 · Cited by 1,944 · cited 2×
“Patients with either cavitary disease or a positive 2-mo culture were combined since their clinical outcomes were similar (13).”
Cegielski, J. P., & McMurray, D. N. (2004) · PubMed · Cited by 801
(1998) · Obesity Research · doi:10.1002/j.1550-8528.1998.tb00690.x · Cited by 758
The curious characteristics of pyrazinamide: a review.
Zhang, Y., & Mitchison, D. A. (2003) · PubMed · Cited by 723
Role of individual drugs in the chemotherapy of tuberculosis.
Mitchison, D. A. (2000) · PubMed · Cited by 319
van Lettow, M., Harries, A. D., Kumwenda, J. J., Zijlstra, E. E., Clark, T. D., Taha, T. E., & Semba, R. D. (2004) · BMC Infectious Diseases · doi:10.1186/1471-2334-4-61 · Cited by 154
Nutritional status in Malawian patients with pulmonary tuberculosis and response to chemotherapy.
Harries, A. D., Nkhoma, W., Thompson, P. J., Nyangulu, D. S., & Wirima, J. J. (1988) · PubMed · Cited by 79
Cited by
Nahid, P., Dorman, S. E., Alipanah, N., Barry, P. M., Brozek, J. L., Cattamanchi, A., Chaisson, L. H., Chaisson, R. E., Daley, C. L., Grzemska, M., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw566 · Cited by 326
Self-citationUndernutrition and Tuberculosis: Public Health Implications
Sinha, P., Davis, J., Saag, L., Wanke, C., Salgame, P., Mesick, J., Horsburgh, C. R., & Hochberg, N. S. (2019) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiy675 · Cited by 204
“Furthermore, insufficient weight gain, defined as ≤ 5% in the first 2 months of treatment, has been associated with higher rates of relapse [45].”
BackgroundSelf-citationClinical Aspects of Adult Tuberculosis
Loddenkemper, R., Lipman, M., & Zumla, A. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017848 · Cited by 140
Evaluation of treatment response in extrapulmonary tuberculosis in a low-resource setting
Jørstad, M. D., Dyrhol-Riise, A. M., Aßmus, J., Marijani, M., Sviland, L., & Mustafa, T. (2019) · BMC Infectious Diseases · doi:10.1186/s12879-019-4034-z · Cited by 32
Metadata
- Authors
- Khan, A., Sterling, T. R., Reves, R., Vernon, A., Horsburgh, C. R., & and the Tuberculosis Trials Consortium
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-08-01
- Volume
- 174
- Issue
- 3
- Pages
- 344-348
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2117226950
- Cited by
- 185
- References
- 10
- FWCI
- 4.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.